Cost-utility of medication withdrawal in older fallers: results from the improving medication prescribing to reduce risk of FALLs (IMPROveFALL) trial

Table 4 Quality of life scores of the control and intervention group at baseline and 12 months follow-up, and the change over 12 months

	Group	N^†	Baseline	Follow-up	p-values*	Change	p-values**
EQ-5D utility score	Control	263	0.78 ± 0.22	0.74 ± 0.25	0.01	−0.04 ± 0.22	0.02
	Intervention	285	0.74 ± 0.26	0.75 ± 0.26	0.75	0.01 ± 0.24
SF-12 PCS score	Control	258	46.2 ± 9.9	42.2 ± 11.6	<0.01	−3.9 ± 8.5	0.08
	Intervention	283	45.6 ± 9.5	43.0 ± 10.7	<0.01	−2.6 ± 8.5
SF-12 MCS score	Control	258	53.2 ± 9.0	52.5 ± 9.2	0.28	−0.7 ± 9.7	0.90
	Intervention	283	53.3 ± 9.5	52.5 ± 9.0	0.20	−0.8 ± 9.7

Data are given as mean values ± standard deviation
^†9 and 23 participants in the control and intervention group declined or were unable to complete EQ-5D questionnaires after 12-months follow-up, an additional 5 and 2 participants in the control and intervention group had incomplete SF-12 questionnaires after 12-months follow-up
*Wilcoxon Signed Rank test (comparing baseline and follow-up)
**Two-way ANOVA of the change over 12 months

ISSN: 1471-2318